Insider transactions

EDGAR

CRISPR THERAPEUTICS AG

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
30 transactions, 327,421.00 shares
Sum of shares × price per share: 17,937,532.5184

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 112

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-17 Filed 2026-11-19Kulkarni Samarth Director · Officer: Chief Executive Officer
G

Bona fide gift

Common Shares
Disposed (D)100,0000.00
0

Derived: shares × price per share. Exact value 0.00.

211,899Direct (D) No— Open filing 0001193125-26-468849 Read from the filing’s XML Dispute this row
2026-11-04 Filed 2026-11-06Sakhamuri Sivakesava Officer: Chief Technical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (90,000) — exercise price 51.78
Acquired (A)90,0000—90,000Direct (D) No
F1
  • F1 This option was granted on November 4, 2026 with respect to 90,000 Common Shares. 25% of the shares shall vest on November 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.
Open filing 0001193125-26-452143 Read from the filing’s XML Dispute this row
2026-11-04 Filed 2026-11-06Sakhamuri Sivakesava Officer: Chief Technical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Shares (40,000)
Acquired (A)40,0000—40,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  • F3 This restricted stock unit award was granted on November 4, 2026 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on November 2, 2027, (ii) one quarter of the shares vesting on November 2, 2028, (iii) one quarter of the shares vesting on November 2, 2029, and (iv) one quarter of the shares vesting on November 2, 2030.
Open filing 0001193125-26-452143 Read from the filing’s XML Dispute this row
2026-10-26 Filed 2026-10-28Kulkarni Samarth Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (57,500) — exercise price 49.01
Acquired (A)57,5000—57,500Direct (D) No
F1
  • F1 This option was granted on October 26, 2026 with respect to 57,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 26, 2026.
Open filing 0001193125-26-436441 Read from the filing’s XML Dispute this row
2026-10-26 Filed 2026-10-28Kulkarni Samarth Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Shares (28,750)
Acquired (A)28,7500—28,750Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  • F3 This restricted stock unit award was granted on October 26, 2026 with respect to 28,750 Common Shares, with (i) one quarter of the shares vesting on October 26, 2027, (ii) one quarter of the shares vesting on October 26, 2028, (iii) one quarter of the shares vesting on October 26, 2029, and (iv) one quarter of the shares vesting on October 26, 2030.
Open filing 0001193125-26-436441 Read from the filing’s XML Dispute this row
2026-10-26 Filed 2026-10-28Patel Naimish Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (24,000) — exercise price 49.01
Acquired (A)24,0000—24,000Direct (D) No
F1
  • F1 This option was granted on October 26, 2026 with respect to 24,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 26, 2026.
Open filing 0001193125-26-436436 Read from the filing’s XML Dispute this row
2026-10-26 Filed 2026-10-28Patel Naimish Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Shares (12,000)
Acquired (A)12,0000—12,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  • F3 This restricted stock unit award was granted on October 26, 2026 with respect to 12,000 Common Shares, with (i) one quarter of the shares vesting on October 26, 2027, (ii) one quarter of the shares vesting on October 26, 2028, (iii) one quarter of the shares vesting on October 26, 2029, and (iv) one quarter of the shares vesting on October 26, 2030.
Open filing 0001193125-26-436436 Read from the filing’s XML Dispute this row
2026-10-26 Filed 2026-10-28Silver Andrew Jacob Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (18,000) — exercise price 49.01
Acquired (A)18,0000—18,000Direct (D) No
F1
  • F1 This option was granted on October 26, 2026 with respect to 18,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 26, 2026.
Open filing 0001193125-26-436444 Read from the filing’s XML Dispute this row
2026-10-26 Filed 2026-10-28Silver Andrew Jacob Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Shares (9,000)
Acquired (A)9,0000—9,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  • F3 This restricted stock unit award was granted on October 26, 2026 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on October 26, 2027, (ii) one quarter of the shares vesting on October 26, 2028, (iii) one quarter of the shares vesting on October 26, 2029, and (iv) one quarter of the shares vesting on October 26, 2030.
Open filing 0001193125-26-436444 Read from the filing’s XML Dispute this row
2026-10-26 Filed 2026-10-28KASINGER JAMES R. Officer: General Counsel and Secretary
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (18,000) — exercise price 49.01
Acquired (A)18,0000—18,000Direct (D) No
F1
  • F1 This option was granted on October 26, 2026 with respect to 18,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 26, 2026.
Open filing 0001193125-26-436443 Read from the filing’s XML Dispute this row
2026-10-26 Filed 2026-10-28KASINGER JAMES R. Officer: General Counsel and Secretary
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Shares (9,000)
Acquired (A)9,0000—9,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  • F3 This restricted stock unit award was granted on October 26, 2026 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on October 26, 2027, (ii) one quarter of the shares vesting on October 26, 2028, (iii) one quarter of the shares vesting on October 26, 2029, and (iv) one quarter of the shares vesting on October 26, 2030.
Open filing 0001193125-26-436443 Read from the filing’s XML Dispute this row
2026-10-19 Filed 2026-10-21Silver Andrew Jacob Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Shares (25,000)
Acquired (A)25,0000—25,000Direct (D) No
F1, F2
  • F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  • F2 This restricted stock unit award was granted on October 19, 2026 with respect to 25,000 Common Shares, with 100% of the shares vesting on October 19, 2028.
Open filing 0001193125-26-428010 Read from the filing’s XML Dispute this row
2026-10-19 Filed 2026-10-20Kulkarni Samarth Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)47,83749.78
2,381,325.86

Derived: shares × price per share. Exact value 2381325.86.

311,899Direct (D) No
F2
  • F2 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
Open filing 0001193125-26-426878 Read from the filing’s XML Dispute this row
2026-10-16 Filed 2026-10-20Kulkarni Samarth Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)100,000——359,736Direct (D) No
F1
  • F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Open filing 0001193125-26-426878 Read from the filing’s XML Dispute this row
2026-10-16 Filed 2026-10-20Kulkarni Samarth Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Shares (100,000)
Disposed (D)100,000——200,000Direct (D) No
F1, F3
  • F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  • F3 This restricted stock unit award was granted on October 16, 2024 with respect to 400,000 Common Shares, with (i) one quarter of the shares vesting on October 16, 2025, (ii) one quarter of the shares vesting on October 16, 2026, (iii) one quarter of the shares vesting on October 16, 2027, and (iv) one quarter of the shares vesting on October 16, 2028.
Open filing 0001193125-26-426878 Read from the filing’s XML Dispute this row
2026-10-14 Filed 2026-10-16George Simeon Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)30,00014
420,000

Derived: shares × price per share. Exact value 420000.

30,000Direct (D) Yes— Open filing 0001193125-26-424317 Read from the filing’s XML Dispute this row
2026-10-14 Filed 2026-10-16George Simeon Director
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)14,51449.6330
720,373.362

Derived: shares × price per share. Exact value 720373.3620.

15,486Direct (D) Yes
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
  • F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.45 to $50.44 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-424317 Read from the filing’s XML Dispute this row
2026-10-14 Filed 2026-10-16George Simeon Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (30,000) — exercise price 14
Disposed (D)30,0000—0Direct (D) Yes
F6
  • F6 This option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016.
Open filing 0001193125-26-424317 Read from the filing’s XML Dispute this row
2026-10-14 Filed 2026-10-15KASINGER JAMES R. Officer: General Counsel and Secretary
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)1,04049.26
51,230.4

Derived: shares × price per share. Exact value 51230.40.

95,857Direct (D) No
F2
  • F2 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
Open filing 0001193125-26-423057 Read from the filing’s XML Dispute this row
2026-10-14 Filed 2026-10-15Kulkarni Samarth Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)4,09849.26
201,867.48

Derived: shares × price per share. Exact value 201867.48.

259,736Direct (D) No
F2
  • F2 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
Open filing 0001193125-26-423056 Read from the filing’s XML Dispute this row
2026-10-13 Filed 2026-10-15KASINGER JAMES R. Officer: General Counsel and Secretary
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)2,113——96,897Direct (D) No
F1
  • F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Open filing 0001193125-26-423057 Read from the filing’s XML Dispute this row
2026-10-13 Filed 2026-10-15KASINGER JAMES R. Officer: General Counsel and Secretary
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Shares (2,113)
Disposed (D)2,113——0Direct (D) No
F1, F3
  • F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  • F3 This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.
Open filing 0001193125-26-423057 Read from the filing’s XML Dispute this row
2026-10-13 Filed 2026-10-15Kulkarni Samarth Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)8,333——263,834Direct (D) No
F1
  • F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Open filing 0001193125-26-423056 Read from the filing’s XML Dispute this row
2026-10-13 Filed 2026-10-15Kulkarni Samarth Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Shares (8,333)
Disposed (D)8,333——0Direct (D) No
F1, F3
  • F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  • F3 This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.
Open filing 0001193125-26-423056 Read from the filing’s XML Dispute this row
2026-10-06 Filed 2026-10-08KASINGER JAMES R. Officer: General Counsel and Secretary
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)1,99013.62
27,103.8

Derived: shares × price per share. Exact value 27103.80.

96,774Direct (D) Yes— Open filing 0001193125-26-418101 Read from the filing’s XML Dispute this row
2026-10-06 Filed 2026-10-08KASINGER JAMES R. Officer: General Counsel and Secretary
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)1,99060.0408
119,481.192

Derived: shares × price per share. Exact value 119481.1920.

94,784Direct (D) Yes
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-418101 Read from the filing’s XML Dispute this row
2026-10-06 Filed 2026-10-08KASINGER JAMES R. Officer: General Counsel and Secretary
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (1,990) — exercise price 13.62
Disposed (D)1,9900.00
0

Derived: shares × price per share. Exact value 0.00.

81,242Direct (D) Yes
F3
  • F3 This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.
Open filing 0001193125-26-418101 Read from the filing’s XML Dispute this row
2026-09-22 Filed 2026-09-24KASINGER JAMES R. Officer: General Counsel and Secretary
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)10,40013.62
141,648

Derived: shares × price per share. Exact value 141648.00.

105,184Direct (D) Yes
F1
  • F1 Includes 476 shares acquired under the CRISPR Therapeutics AG 2026 Employee Stock Purchase Plan.
Open filing 0001193125-26-401237 Read from the filing’s XML Dispute this row
2026-09-22 Filed 2026-09-24KASINGER JAMES R. Officer: General Counsel and Secretary
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)10,40060.2365
626,459.6

Derived: shares × price per share. Exact value 626459.6000.

94,784Direct (D) Yes
F2, F3
  • F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.
  • F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Open filing 0001193125-26-401237 Read from the filing’s XML Dispute this row
2026-09-22 Filed 2026-09-24KASINGER JAMES R. Officer: General Counsel and Secretary
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (10,400) — exercise price 13.62
Disposed (D)10,4000.00
0

Derived: shares × price per share. Exact value 0.00.

83,232Direct (D) Yes
F4
  • F4 This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.
Open filing 0001193125-26-401237 Read from the filing’s XML Dispute this row
2026-09-17 Filed 2026-09-21Behbahani Ali Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)30,00014
420,000

Derived: shares × price per share. Exact value 420000.

30,316Direct (D) No— Open filing 0001193125-26-396944 Read from the filing’s XML Dispute this row
2026-09-17 Filed 2026-09-21Behbahani Ali Director
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)13,67957.0901
780,935.4779

Derived: shares × price per share. Exact value 780935.4779.

16,637Direct (D) No
F1
  • F1 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.97 to $57.43 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-396944 Read from the filing’s XML Dispute this row
2026-09-17 Filed 2026-09-21Behbahani Ali Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (30,000) — exercise price 14
Disposed (D)30,0000—0Direct (D) No
F3
  • F3 This option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016.
Open filing 0001193125-26-396944 Read from the filing’s XML Dispute this row
2026-08-07 Filed 2026-08-11Prasad Raju Officer: Chief Financial Officer
G

Bona fide gift

Common Shares
Disposed (D)7500.00
0

Derived: shares × price per share. Exact value 0.00.

14,815Direct (D) No— Open filing 0001193125-26-345111 Read from the filing’s XML Dispute this row
2026-06-05 Filed 2026-06-09George Simeon Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (13,000) — exercise price 51.84
Acquired (A)13,0000—13,000Direct (D) No
F1
  • F1 Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Open filing 0001193125-26-264390 Read from the filing’s XML Dispute this row
2026-06-05 Filed 2026-06-09High Katherine A Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (13,000) — exercise price 51.84
Acquired (A)13,0000—13,000Direct (D) No
F1
  • F1 Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Open filing 0001193125-26-264287 Read from the filing’s XML Dispute this row
2026-06-05 Filed 2026-06-09Rommel Christian Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (13,000) — exercise price 51.84
Acquired (A)13,0000—13,000Direct (D) No
F1
  • F1 Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Open filing 0001193125-26-264282 Read from the filing’s XML Dispute this row
2026-06-05 Filed 2026-06-09Mahatme Sandesh Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (13,000) — exercise price 51.84
Acquired (A)13,0000—13,000Direct (D) No
F1
  • F1 Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Open filing 0001193125-26-264286 Read from the filing’s XML Dispute this row
2026-06-05 Filed 2026-06-09Treco Douglas A Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (13,000) — exercise price 51.84
Acquired (A)13,0000—13,000Direct (D) No
F1
  • F1 Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Open filing 0001193125-26-264279 Read from the filing’s XML Dispute this row
2026-06-05 Filed 2026-06-09Greene John Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (13,000) — exercise price 51.84
Acquired (A)13,0000—13,000Direct (D) No
F1
  • F1 Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Open filing 0001193125-26-264288 Read from the filing’s XML Dispute this row
2026-06-05 Filed 2026-06-09Fardis Maria Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (13,000) — exercise price 51.84
Acquired (A)13,0000—13,000Direct (D) No
F1
  • F1 Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Open filing 0001193125-26-264290 Read from the filing’s XML Dispute this row
2026-06-05 Filed 2026-06-09Fleming Harold Edward Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (13,000) — exercise price 51.84
Acquired (A)13,0000—13,000Direct (D) No
F1
  • F1 Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Open filing 0001193125-26-264289 Read from the filing’s XML Dispute this row
2026-06-05 Filed 2026-06-09Behbahani Ali Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (13,000) — exercise price 51.84
Acquired (A)13,0000—13,000Direct (D) No
F1
  • F1 Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Open filing 0001193125-26-264382 Read from the filing’s XML Dispute this row
2026-06-05 Filed 2026-06-09Morrison Briggs Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Shares (13,000) — exercise price 51.84
Acquired (A)13,0000—13,000Direct (D) No
F1
  • F1 Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Open filing 0001193125-26-264285 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02Prasad Raju Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Shares (19,500)
Acquired (A)19,5000—19,500Direct (D) No
F1, F2
  • F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  • F2 This restricted stock unit award was granted on May 29, 2026 with respect to 19,500 Common Shares, with 100% of the shares vesting on November 29, 2028.
Open filing 0001193125-26-253925 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02Patel Naimish Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Shares (22,000)
Acquired (A)22,0000—22,000Direct (D) No
F1, F2
  • F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  • F2 This restricted stock unit award was granted on May 29, 2026 with respect to 22,000 Common Shares, with 100% of the shares vesting on November 29, 2028.
Open filing 0001193125-26-253926 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02KASINGER JAMES R. Officer: General Counsel and Secretary
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Shares (17,000)
Acquired (A)17,0000—17,000Direct (D) No
F1, F2
  • F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  • F2 This restricted stock unit award was granted on May 29, 2026 with respect to 17,000 Common Shares, with 100% of the shares vesting on November 29, 2028.
Open filing 0001193125-26-253929 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-01Patel Naimish Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Shares
Disposed (D)3,78655.62
210,577.32

Derived: shares × price per share. Exact value 210577.32.

19,357Direct (D) No
F2
  • F2 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
Open filing 0001193125-26-251817 Read from the filing’s XML Dispute this row
2026-05-28 Filed 2026-06-01Patel Naimish Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Shares
Acquired (A)10,000——23,143Direct (D) No
F1
  • F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Open filing 0001193125-26-251817 Read from the filing’s XML Dispute this row
2026-05-28 Filed 2026-06-01Patel Naimish Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Shares (10,000)
Disposed (D)10,000——20,000Direct (D) No
F1, F3
  • F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  • F3 This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028.
Open filing 0001193125-26-251817 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–50 of 543

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
ARK Investment Management LLC 10,056,844 SH556,344,632 dollarsHigher by 595,905 Prior quarter: 9,460,939Open filing 0001104659-26-126785 Filed 2026-11-13 Dispute this row
BlackRock, Inc. Partly reported under another manager8,299,872 SH459,148,910 dollarsLower by 49,105 Prior quarter: 8,348,977Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
STATE STREET CORP Partly reported under another manager4,994,047 SH276,270,680 dollarsHigher by 672,381 Prior quarter: 4,321,666Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
Capital World Investors Partly reported under another manager4,739,139 SH262,169,169 dollarsLower by 10,386 Prior quarter: 4,749,525Open filing 0001422849-26-000169 Filed 2026-11-12 Dispute this row
Orbis Allan Gray Ltd Partly reported under another manager4,519,261 SH250,005,518 dollarsLower by 929,900 Prior quarter: 5,449,161Open filing 0001663865-26-000005 Filed 2026-11-16 Dispute this row
GSK plc 2,608,419 SH144,297,739 dollarsLower by 612,208 Prior quarter: 3,220,627Open filing 0001999371-26-024635 Filed 2026-11-05 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager2,512,203 SH139,002,793 dollarsHigher by 2,288 Prior quarter: 2,509,915Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
SR ONE CAPITAL MANAGEMENT, LP 2,038,763 SH112,784,369 dollarsUnchanged Prior quarter: 2,038,763Open filing 0001012975-26-001062 Filed 2026-11-16 Dispute this row
TWO SIGMA INVESTMENTS, LP 2,016,038 SH111,527,222 dollarsHigher by 27,417 Prior quarter: 1,988,621Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
FMR LLC Partly reported under another manager1,896,744 SH104,927,875 dollarsLower by 11,759 Prior quarter: 1,908,503Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager1,739,319 SH96,219,108 dollarsHigher by 584,214 Prior quarter: 1,155,105Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
T. Rowe Price Investment Management, Inc. 1,657,347 SH91,685 dollarsLower by 395,670 Prior quarter: 2,053,017Open filing 0001897612-26-000766 Filed 2026-11-16 Dispute this row
Sumitomo Mitsui Trust Group, Inc. Partly reported under another manager1,453,713 SH80,419,403 dollarsLower by 267,021 Prior quarter: 1,720,734Open filing 0001214659-26-013361 Filed 2026-10-29 Dispute this row
Amova Asset Management Americas, Inc. Partly reported under another manager1,453,513 SH80,364,734 dollarsLower by 266,584 Prior quarter: 1,720,097Open filing 0001140361-26-043552 Filed 2026-11-13 Dispute this row
EcoR1 Capital, LLC 1,389,276 SH76,854,748 dollarsUnchanged Prior quarter: 1,389,276Open filing 0000935836-26-000577 Filed 2026-11-16 Dispute this row
Capital International Investors Partly reported under another manager1,266,283 SH70,050,776 dollarsLower by 2,124 Prior quarter: 1,268,407Open filing 0001562230-26-000136 Filed 2026-11-12 Dispute this row
UBS Group AG Partly reported under another manager1,248,620 SH69,073,659 dollarsLower by 68,879 Prior quarter: 1,317,499Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 1,170,146 SH64,732,477 dollarsLower by 11,701 Prior quarter: 1,181,847Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1,137,467 SH62,924,674 dollarsHigher by 79,630 Prior quarter: 1,057,837Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
NEA Management Company, LLC 1,058,570 SH58,560,092 dollarsUnchanged Prior quarter: 1,058,570Open filing 0001072613-26-000901 Filed 2026-11-16 Dispute this row
HRT FINANCIAL LP 901,054 SH49,846 dollarsHigher by 758,490 Prior quarter: 142,564Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row
MORGAN STANLEY Partly reported under another manager842,105 SH46,585,376 dollarsLower by 37,844 Prior quarter: 879,949Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager833,105 SH46,087,368 dollarsLower by 29,986 Prior quarter: 863,091Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 649,730 SH35,943,064 dollarsHigher by 1,017 Prior quarter: 648,713Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Partly reported under another manager610,688 SH33,783,260 dollarsHigher by 183,510 Prior quarter: 427,178Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 573,551 SH31,728,841 dollarsHigher by 3,511 Prior quarter: 570,040Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager518,906 SH28,705,880 dollarsLower by 374,906 Prior quarter: 893,812Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Put Partly reported under another manager503,800 SH27,870,216 dollarsHigher by 165,400 Prior quarter: 338,400Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
Nuveen, LLC Partly reported under another manager496,160 SH27,447,571 dollarsHigher by 293,071 Prior quarter: 203,089Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
CITADEL ADVISORS LLC Option: Put Partly reported under another manager470,700 SH26,039,124 dollarsHigher by 180,600 Prior quarter: 290,100Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
IQ EQ FUND MANAGEMENT (IRELAND) Ltd 391,170 SH21,639,524 dollarsHigher by 9,179 Prior quarter: 381,991Open filing 0001213900-26-119414 Filed 2026-11-13 Dispute this row
ROYAL BANK OF CANADA Partly reported under another manager361,956 SH20,024,000 dollarsHigher by 188,911 Prior quarter: 173,045Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Call Partly reported under another manager356,900 SH19,743,708 dollarsHigher by 31,200 Prior quarter: 325,700Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
AMERICAN CENTURY COMPANIES INC Partly reported under another manager355,848 SH19,685,512 dollarsHigher by 216,386 Prior quarter: 139,462Open filing 0000748054-26-000009 Filed 2026-11-20 Dispute this row
Baird Financial Group, Inc. Partly reported under another manager354,005 SH19,583,557 dollarsNot in the prior quarter’s filings read Open filing 0001648711-26-000011 Filed 2026-11-13 Dispute this row
JANE STREET GROUP, LLC Option: Call Partly reported under another manager346,900 SH19,190,508 dollarsHigher by 116,500 Prior quarter: 230,400Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
Man Group plc Partly reported under another manager329,602 SH18,233,583 dollarsHigher by 256,408 Prior quarter: 73,194Open filing 0001637460-26-000004 Filed 2026-11-16 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager316,711 SH17,520,443 dollarsLower by 10,050 Prior quarter: 326,761Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
IMC-Chicago, LLC Option: Call 300,000 SH16,596,000 dollarsLower by 5,800 Prior quarter: 305,800Open filing 0001452861-26-000007 Filed 2026-11-05 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager286,017 SH16,310,553 dollarsLower by 145,652 Prior quarter: 431,669Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager260,814 SH14,428,343 dollarsHigher by 10,200 Prior quarter: 250,614Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager259,016 SH14,334,525 dollarsLower by 16,359 Prior quarter: 275,375Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
Logos Global Management LP 250,000 SH13,830,000 dollarsLower by 50,000 Prior quarter: 300,000Open filing 0001172661-26-005476 Filed 2026-11-19 Dispute this row
PEAK6 LLC Option: Call Partly reported under another manager245,700 SH13,592,124 dollarsHigher by 175,400 Prior quarter: 70,300Open filing 0001389958-26-000020 Filed 2026-11-13 Dispute this row
RAYMOND JAMES FINANCIAL INC Partly reported under another manager232,977 SH12,888,288 dollarsHigher by 989 Prior quarter: 231,988Open filing 0000720005-26-000081 Filed 2026-11-12 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager230,981 SH12,777,868 dollarsLower by 41,391 Prior quarter: 272,372Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
Vestmark Advisory Solutions, Inc. Partly reported under another manager212,932 SH11,779,399 dollarsLower by 29,334 Prior quarter: 242,266Open filing 0001172661-26-005184 Filed 2026-11-16 Dispute this row
Russell Investments Group, Ltd. Partly reported under another manager212,645 SH11,763,521 dollarsHigher by 136,379 Prior quarter: 76,266Open filing 0001193125-26-451241 Filed 2026-11-06 Dispute this row
CITADEL ADVISORS LLC Option: Call Partly reported under another manager207,300 SH11,467,836 dollarsLower by 48,900 Prior quarter: 256,200Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
WELLS FARGO COMPANY/MN Partly reported under another manager193,537 SH10,706,453 dollarsLower by 69,632 Prior quarter: 263,169Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Sixth Street Partners Management Company, L.P. 1,057,837 SH
  • NORGES BANK 270,756 SH
  • Campbell CO Investment Adviser LLC 107,529 SH
  • Jupiter Topco LLC 40,274 SH
  • West Family Investments, Inc. 35,500 SH
  • GUGGENHEIM CAPITAL LLC 35,490 SH
  • Curated Wealth Partners LLC 35,000 SH
  • Arete Wealth Advisors, LLC 29,626 SH
  • SG Americas Securities, LLC 28,185 SH
  • Headlands Technologies LLC 24,180 SH
  • Jefferies Financial Group Inc. 24,001 SH
  • Jain Global LLC 21,700 SH
  • Inspire Advisors, LLC 19,880 SH
  • Abu Dhabi Investment Council Co P.J.S.C 18,958 SH
  • SFE Investment Counsel 16,700 SH
  • BRAVE ASSET MANAGEMENT INC 11,234 SH
  • NLB Skladi, upravljanje premozenja, d.o.o. 11,111 SH
  • IMC-Chicago, LLC 10,709 SH
  • FOX RUN MANAGEMENT, L.L.C. 10,490 SH
  • Arkadios Wealth Advisors 10,487 SH
  • TWO SIGMA SECURITIES, LLC 10,341 SH
  • AXQ CAPITAL, LP 9,634 SH
  • Jupiter Wealth Management LLC 8,500 SH
  • Diametric Capital, LP 6,398 SH
  • D. E. Shaw Co., Inc. 6,100 SH
  • Bellevue Group AG 5,818 SH
  • SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC 5,702 SH
  • PRELUDE CAPITAL MANAGEMENT, LLC 5,474 SH
  • Abundance Wealth Counselors 5,015 SH
  • PSP Research LLC 5,000 SH
  • CAPITAL ADVISORS INC/OK 4,990 SH
  • KEYNOTE FINANCIAL SERVICES LLC 4,758 SH
  • NORTH STAR ASSET MANAGEMENT INC 4,525 SH
  • Squarepoint Ops LLC 4,200 SH
  • StoneX Group Inc. 4,133 SH
  • Global Assets Advisory, LLC 4,010 SH
  • James J. Burns Company, LLC 3,855 SH
  • JANE STREET GROUP, LLC 3,780 SH
  • Retirement Planning Group, LLC 3,720 SH
  • Kingsview Wealth Management, LLC 3,672 SH
  • UMB Bank, n.a. 2,870 SH
  • Turn8 Private Wealth Inc. 2,556 SH
  • UBS Group AG 2,500 SH
  • HM PAYSON CO 2,320 SH
  • MCF Advisors LLC 2,187 SH
  • Aberdeen Wealth Management LLC 2,110 SH
  • Concurrent Investment Advisors, LLC 2,000 SH
  • Axiom Investment Management LLC 1,520 SH
  • Itau Unibanco Holding S.A. 1,095 SH
  • Pacer Advisors, Inc. 932 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

Showing 1–3 of 3

House members’ trades in this company, newest report first, as filed
MemberTransaction dateTypeAmountOwnerReport
Hon. Thomas Suozzi (NY03)2021-09-20Sale$50,001 - $100,0002021-10-05
Hon. Thomas Suozzi (NY03)2021-06-03Purchase$50,001 - $100,0002021-09-23
Mrs. Marjorie Taylor Greene (GA14)2021-01-21Purchase$1,001 - $15,000JT2021-02-19

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
ORBIS INVESTMENT MANAGEMENT LTD Common Stock4.74,501,78209/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000940594-26-000069 Dispute this row
Allan Gray Australia Pty Ltd Common Stock017,47909/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0000940594-26-000069 Dispute this row
ARK Investment Management LLC Common Stock10.4010,056,844.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 14Open filing 0001104659-26-126825 Dispute this row
Catherine D. Wood Common Stock10.4010,056,844.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 14Open filing 0001104659-26-126825 Dispute this row
STATE STREET CORPORATION COMMON STOCK5.24,994,047.0009/30/2026 Filed 2026-11-10SCHEDULE 13GOpen filing 0000093751-26-000637 Dispute this row
ORBIS INVESTMENT MANAGEMENT LTD Common Stock5.65,433,34406/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 3Open filing 0000940594-26-000049 Dispute this row
Allan Gray Australia Pty Ltd Common Stock015,81706/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 3Open filing 0000940594-26-000049 Dispute this row
BlackRock, Inc. Common Stock8.37,987,26206/30/2026 Filed 2026-07-27SCHEDULE 13G/AAmendment 1Open filing 0002012383-26-002146 Dispute this row
ORBIS INVESTMENT MANAGEMENT LTD Common Stock6.36,090,19403/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0000940594-26-000027 Dispute this row
Allan Gray Australia Pty Ltd Common Stock015,81703/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0000940594-26-000027 Dispute this row
Capital World Investors Common Stock5.14,929,428.0003/31/2026 Filed 2026-05-14SCHEDULE 13GOpen filing 0001422849-26-000051 Dispute this row
ARK Investment Management LLC Common Stock11.7911,313,623.0003/31/2026 Filed 2026-04-30SCHEDULE 13G/AAmendment 13Open filing 0001104659-26-052492 Dispute this row
Catherine D. Wood Common Stock11.7911,313,623.0003/31/2026 Filed 2026-04-30SCHEDULE 13G/AAmendment 13Open filing 0001104659-26-052492 Dispute this row
Capital International Investors Common Stock1.21,186,794.0001/30/2026 Filed 2026-02-05SCHEDULE 13G/AAmendment 4Open filing 0001562230-26-000001 Dispute this row
ORBIS INVESTMENT MANAGEMENT LTD Common Stock6.25,934,32812/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000940594-26-000006 Dispute this row
Allan Gray Australia Pty Ltd Common Stock015,81712/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000940594-26-000006 Dispute this row
ORBIS INVESTMENT MANAGEMENT LTD Common Stock5.54,974,12509/30/2025 Filed 2025-11-14SCHEDULE 13GOpen filing 0000940594-25-000008 Dispute this row
Allan Gray Australia Pty Ltd Common Stock07,96009/30/2025 Filed 2025-11-14SCHEDULE 13GOpen filing 0000940594-25-000008 Dispute this row
ARK Investment Management LLC Common Stock10.769,786,973.0009/30/2025 Filed 2025-11-04SCHEDULE 13G/AAmendment 12Open filing 0001104659-25-106355 Dispute this row
Catherine D. Wood Common Stock10.769,786,973.0009/30/2025 Filed 2025-11-04SCHEDULE 13G/AAmendment 12Open filing 0001104659-25-106355 Dispute this row
BlackRock, Inc. Common Stock6.95,932,43306/30/2025 Filed 2025-07-17SCHEDULE 13GOpen filing 0002052113-25-002963 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,687,210 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015103,592
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to CRISPR THERAPEUTICS AG